Trial results

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

NCT06649344 on ClinicalTrials.gov · last registry update 2026-07-30

An unusually large phase 3: 884 participants, more than double the 424 typical for the stage. The sponsor logged completion for 18 July 2026. Primary outcome, as filed: Change in HbA1c. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.

Sponsor type

Industry

Enrollment

884

Started

2024-10-31

Primary completion

2026-07-18 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.